RT Journal Article SR Electronic T1 Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015 to 2024; an observational study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.08.12.24311674 DO 10.1101/2024.08.12.24311674 A1 Fifer, Helen A1 Doumith, Michel A1 Rubinstein, Luciana A1 Mitchell, Laura A1 Wallis, Mark A1 Singh, Selena A1 Singh, Gurmit Jagjit A1 Rayment, Michael A1 Evans-Jones, John A1 Blume, Alison A1 Dosekun, Olamide A1 Poon, Kenny A1 Nori, Achyuta A1 Day, Michaela A1 Pitt, Rachel A1 Sun, Suzy A1 Narayanan, Prarthana A1 Callan, Emma A1 Vickers, Anna A1 Minshull, Jack A1 Bennet, Kirsty A1 Johnson, James E.C. A1 Saunders, John A1 Alexander, Sarah A1 Mohammed, Hamish A1 Woodford, Neil A1 Sinka, Katy A1 Cole, Michelle YR 2024 UL http://medrxiv.org/content/early/2024/08/17/2024.08.12.24311674.abstract AB Background Since June 2022, there has been a rise in the number of ceftriaxone resistant Neisseria gonorrhoeae cases detected in England (n = 15), of which one third were extensively-drug resistant (XDR). We describe the demographic and clinical details of the recent cases and investigate the phenotypic and molecular characteristics of the isolates. For a comprehensive overview, we also reviewed 16 ceftriaxone-resistant cases previously identified in England since December 2015 and performed a global genomic comparison of all publicly available ceftriaxone-resistant N. gonorrhoeae strains with mosaic penA alleles.Methods All N. gonorrhoeaeisolates resistant to ceftriaxone (MIC >0.125 mg/L) were whole-genome sequenced and compared with 142 global sequences of ceftriaxone-resistant N. gonorrhoeae. Demographic, behavioural, and clinical data were collected, including treatment and outcomes.Results All cases were heterosexuals, and most infections were associated with travel to or from the Asia-Pacific region. However, some had not travelled outside England within the previous few months. There were no ceftriaxone genital treatment failures, but 3/5 pharyngeal infections and the only rectal infection failed treatment. The isolates represented 13 different multi-locus sequence types (MLSTs), and most had the mosaic penA-60.001 allele. The global genomes clustered into eight major phylogroups, with regional associations. All XDR isolates belonged to the same phylogroup, represented by MLST 16406.Conclusion Ceftriaxone resistance in N. gonorrhoeae continues to be associated with the penA-60.001 allele within multiple genetic backgrounds and with widespread dissemination in the Asia-Pacific region. Heightened surveillance activities have been initiated to detect further cases with the aim of interrupting further transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by UKHSAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics and Governance Group of the UK Health Security Agency waived ethical approval for this work. This analysis was undertaken for health protection purposes under permissions granted to UKHSA to collect and process confidential patient data under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2020 and Section 251 of the National Health Service Act 2006.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.